JP6027710B1 - 糖尿病治療用固形製剤 - Google Patents

糖尿病治療用固形製剤 Download PDF

Info

Publication number
JP6027710B1
JP6027710B1 JP2016546861A JP2016546861A JP6027710B1 JP 6027710 B1 JP6027710 B1 JP 6027710B1 JP 2016546861 A JP2016546861 A JP 2016546861A JP 2016546861 A JP2016546861 A JP 2016546861A JP 6027710 B1 JP6027710 B1 JP 6027710B1
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
canagliflozin
weight
tenerigliptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546861A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2016104643A1 (ja
Inventor
淳 今井
淳 今井
一樹 越智
一樹 越智
卓之 徳田
卓之 徳田
諒一 古川
諒一 古川
竜也 伊藤
竜也 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of JP6027710B1 publication Critical patent/JP6027710B1/ja
Publication of JPWO2016104643A1 publication Critical patent/JPWO2016104643A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016546861A 2014-12-25 2015-12-24 糖尿病治療用固形製剤 Active JP6027710B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014262702 2014-12-25
JP2014262702 2014-12-25
PCT/JP2015/086097 WO2016104643A1 (ja) 2014-12-25 2015-12-24 糖尿病治療用固形製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202730A Division JP6639368B2 (ja) 2014-12-25 2016-10-14 糖尿病治療用固形製剤

Publications (2)

Publication Number Publication Date
JP6027710B1 true JP6027710B1 (ja) 2016-11-16
JPWO2016104643A1 JPWO2016104643A1 (ja) 2017-04-27

Family

ID=56150656

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546861A Active JP6027710B1 (ja) 2014-12-25 2015-12-24 糖尿病治療用固形製剤
JP2016202730A Active JP6639368B2 (ja) 2014-12-25 2016-10-14 糖尿病治療用固形製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202730A Active JP6639368B2 (ja) 2014-12-25 2016-10-14 糖尿病治療用固形製剤

Country Status (2)

Country Link
JP (2) JP6027710B1 (enExample)
WO (1) WO2016104643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039402B1 (ru) * 2017-02-03 2022-01-24 Гленмарк Фармасьтикалз Лимитед Оксалаты тенелиглиптина и их сольваты, промежуточные соединения, способ получения и их маркеры
WO2020209350A1 (ja) * 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
WO2024053680A1 (ja) * 2022-09-07 2024-03-14 田辺三菱製薬株式会社 口腔内崩壊錠

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517937A (ja) * 2007-02-01 2010-05-27 武田薬品工業株式会社 アログリプチンおよびピオグリタゾンを含有する固形製剤
JP2011509922A (ja) * 2008-01-17 2011-03-31 田辺三菱製薬株式会社 Ｓｇｌｔ阻害剤及びｄｐｐ４阻害剤からなる併用療法
WO2011074660A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 溶出安定性製剤
JP2012517458A (ja) * 2009-02-13 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチン及び必要に応じてｓｇｌｔ２阻害薬を含む医薬組成物、並びにその使用
JP2013526482A (ja) * 2010-05-11 2013-06-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517937A (ja) * 2007-02-01 2010-05-27 武田薬品工業株式会社 アログリプチンおよびピオグリタゾンを含有する固形製剤
JP2011509922A (ja) * 2008-01-17 2011-03-31 田辺三菱製薬株式会社 Ｓｇｌｔ阻害剤及びｄｐｐ４阻害剤からなる併用療法
JP2012517458A (ja) * 2009-02-13 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチン及び必要に応じてｓｇｌｔ２阻害薬を含む医薬組成物、並びにその使用
WO2011074660A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 溶出安定性製剤
JP2013526482A (ja) * 2010-05-11 2013-06-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
木下秀司ら: "新規ＳＧＬＴ２阻害薬カナグリフロジンとＤＰＰ−４阻害薬テネリグリプチンの健康成人における薬物動態及び", 糖尿病, vol. 57, no. 1, JPN6016008635, 25 April 2014 (2014-04-25), pages 173, ISSN: 0003410113 *
木内智子ら: "Ｚｕｃｋｅｒ Ｄｉａｂｅｔｉｃ Ｆａｔｔｙラットにおけるテネリグリプチンと新規ＳＧＬＴ２阻害薬カナグ", 糖尿病, vol. 57, no. 1, JPN6016008636, 25 April 2014 (2014-04-25), pages 313, ISSN: 0003410114 *

Also Published As

Publication number Publication date
JP6639368B2 (ja) 2020-02-05
JP2017002092A (ja) 2017-01-05
JPWO2016104643A1 (ja) 2017-04-27
WO2016104643A1 (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
JP4989733B2 (ja) 口腔内崩壊錠
US8673353B2 (en) Tablet having improved elution properties
KR100534504B1 (ko) 속붕괴성 의약 조성물
CN101646420B (zh) 包含阿格列汀和吡格列酮的固体制剂
JP5162475B2 (ja) ピオグリタゾンを含有する経口剤
JP6054940B2 (ja) １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含有する固形医薬組成物
EP1962811B1 (en) Solid preparation containing an insulin sensitizer
JP2019069981A (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP6027710B1 (ja) 糖尿病治療用固形製剤
JP2020196713A (ja) エドキサバンを含有する口腔内崩壊錠
US20120010216A1 (en) Pharmaceutical compositions containing vanoxerine
JP6107226B2 (ja) 医薬組成物
JP2022140430A (ja) リバーロキサバン含有錠剤
KR20150021544A (ko) 고형 제제
JPWO2015199115A1 (ja) 経口投与用医薬組成物
JP2020070287A (ja) 口腔内崩壊錠及びその製造方法
JP5226732B2 (ja) 催眠用圧縮成型製剤
KR102488167B1 (ko) 피롤카르복사미드의 고형 조성물
CN104174022B (zh) 一种吡格列酮的苦味抑制剂和包含吡格列酮的口服制剂
WO2023175573A1 (en) Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
JP6110589B2 (ja) ロキソプロフェンナトリウムとクレマスチンフマル酸塩を含有する固形製剤
JP2022021916A (ja) イストラデフィリン含有口腔内崩壊錠
HK1247826B (en) Solid composition of pyrrole carboxamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160714

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160714

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161014

R150 Certificate of patent or registration of utility model

Ref document number: 6027710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250